Top 5 worldwide oncology products by market share 2017 and 2024

This statistic displays the top oncology products worldwide by projected market share for 2024, and their market shares in 2017. Cancer drug Opdivo from Bristol-Myers Squibb and Ono Pharmaceutical is expected to keep its position with a market share of five percent.

Top oncology products

Oncological products generate a significant proportion of their revenue in the United States and in Europe. In 2012, oncology spending totaled nearly 50 billion U.S. dollars in the United States and 22 billion U.S. dollars in the leading five EU-countries. Oncology is among the top therapy classes in the pharmaceutical market.

Among the top oncology products in 2017 were Keytruda and Opdivo, generating 3.8 and 5.7 billion U.S. dollars on the worldwide market. Top cancer drug Rituxan is marketed by Roche and is used to treat diseases such as lymphomas, leukemias, transplant rejections, and autoimmune disorders. Bevacizumab, marketed as Avastin also under Roche, is used to slow down the growth rate of new blood vessels. It can be used to treat cancers such as those originating in the colorectum, lung, breast, or kidney. Roche has a stronghold on the global oncology market. In 2017, Roche maintained a share of over 26 percent of the market but is expected to drop to some 12 percent of the market in 2024. Roche or Hoffman-La Roche is a Swiss company that was founded in 1896. The company focuses primarily on pharmaceutical products and diagnostics. Roche generated more than 53 billion Swiss francs in revenue in 2017, making it one of the most successful biotech and pharmaceutical companies in the world.

Top 5 oncology products worldwide by market share in 2017 and 2024

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until October 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

June 2018



Survey time period

as of May 2018

Supplementary notes

Oncology includes: Alkaloids, alkylating agents, anti-metabolites, anti-neoplastic MAbs, cancer vaccines, cytotoxic antibiotics, cormone therapies, platinum compounds and other anti-cancer. Excludes anti-emetics and anti-anaemics used in chemotherapy-induced anaemia. Also excludes: Interferons, immunostimulants & immunosuppressants.
The products are ranked by 2024 market share.
* Projected.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Oncology"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.